The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Kling Douglas F since 2025.
This trader's CIK number is 1699022.
At the time of last reporting, Kling Douglas F was the Chief Operating Officer of Newamsterdam Pharma Co N.v.. (stock ticker symbol NAMS).
Also see all insider trading activities at Newamsterdam Pharma Co N.v..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | NAMS | 0 | $0 | 616,539 | $1,947,000 | 616,539 | $3,544,999 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-06-16 | NAMS | Option Ex | 100,000 | 10.45 | 1,044,999 |
| 2025-06-16 | NAMS | Sale | 100,000 | 19.47 | 1,947,000 |
| 2025-05-15 | NAMS | Option Ex | 100,000 | 10.00 | 1,000,000 |
| 2025-05-15 | NAMS | Sale | 100,000 | .00 | 0 |
| 2025-04-15 | NAMS | Option Ex | 100,000 | 10.00 | 1,000,000 |
| 2025-04-15 | NAMS | Sale | 100,000 | .00 | 0 |
| 2025-03-26 | NAMS | Option Ex | 16,539 | .00 | 0 |
| 2025-03-26 | NAMS | Sale | 16,539 | .00 | 0 |
| 2025-03-17 | NAMS | Option Ex | 100,000 | 5.00 | 500,000 |
| 2025-03-17 | NAMS | Sale | 100,000 | .00 | 0 |
| 2025-01-29 | NAMS | Sale | 56,863 | .00 | 0 |
| 2025-01-30 | NAMS | Sale | 13,578 | .00 | 0 |
| 2025-01-29 | NAMS | Option Ex | 56,863 | .00 | 0 |
| 2025-01-30 | NAMS | Option Ex | 13,578 | .00 | 0 |
| 2025-01-27 | NAMS | Option Ex | 104,174 | .00 | 0 |
| 2025-01-28 | NAMS | Option Ex | 25,385 | .00 | 0 |
| 2025-01-27 | NAMS | Sale | 104,174 | .00 | 0 |
| 2025-01-28 | NAMS | Sale | 25,385 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Kling Douglas F (Chief Operating Officer of Newamsterdam Pharma Co N.v. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.